STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #407 by analyst upside · 2026-06-27
PROK
ProKidney Corp.
Healthcare · Market Cap $553M · P/E 0x
ANALYST PRICE TARGET
+241.5%
implied upside to consensus target
Current Price $1.83
Consensus Target $6.25
Bull Target $12.0
Bear Target $1.0
Analysts Covering 6
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
3
Hold
2
Sell
1
52-Week Low $0.54
52-Week High $7.13
YTD Return -17.9%
FUNDAMENTALS
Market Cap $553M
P/E Ratio (TTM) N/A
Forward P/E -3.2x
EPS (TTM) $-0.57
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.54
52-Week High $7.13
Current Price $1.83
Bear Target $1.0
Bull Target $12.0
● Now $1.83 ● Target $6.25
TRADING DATA
Avg Volume 941K
YTD Return -17.9%
Analyst Count 6
Consensus Hold
Upside to Target +241.5%
Last Updated 2026-06-27

ANALYST SUMMARY

ProKidney Corp. (PROK) is currently trading at $1.83 with a Wall Street consensus price target of $6.25, implying potential upside of 241.5% over the next 12 months. 6 analysts currently cover PROK, with a consensus rating of Hold - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $1.0.

PROK operates in the Healthcare sector with a market capitalisation of $553M. The stock is down 17.9% year-to-date and is currently trading near the lower end of its 52-week range of $0.54 – $7.13.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PROK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-18 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2025-12-16 31% win rate (48 calls)
UBS — Reiterated
Buy → Buy 2025-07-15 33% win rate (6 calls)
Guggenheim — Reiterated
Buy → Buy 2025-07-14 62% win rate (8 calls)
Citigroup — Reiterated
Buy → Buy 2025-07-09 Building track record
B of A Securities ↓ Downgrade
Neutral → Underperform 2025-06-30 Building track record
JP Morgan ● Initiated
Neutral 2024-09-30 43% win rate (7 calls)
Guggenheim ● Initiated
Buy 2024-09-10 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
22
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →